All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @itsmevon49 on TikTok · 199s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @itsmevon49's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00From a day late, having a heart attack guys.
  2. 0:04I was so busy yesterday, running around doing all sorts
  3. 0:08and I didn't get time to take my rejection.
  4. 0:11So I'm doing it today.
  5. 0:13That means I'm 24 hours late.
  6. 0:14It's not a big deal, okay?
  7. 0:16I was panicking yesterday, but I am not panicking today
  8. 0:20because it is what it is, you know.
  9. 0:24I have lost, I've just weighed.
  10. 0:26I have lost two kilograms, I think.
  11. 0:31So, yeah.
  12. 0:34That being said, I've been getting lots of messages
  13. 0:37from people asking me, you know, any tips, any advice.
  14. 0:43All I can really say is just relax.
  15. 0:46I think that's the biggest thing with this.
  16. 0:49So I'm like, this thing, do this thing, okay?
  17. 0:52But what I would say is this is just a tool.
  18. 0:54We have to change our thought process on food choices.
  19. 0:58You can't take this and still go out and eat
  20. 1:01everything that we're used to.
  21. 1:03And expect to lose weight just because you're taking
  22. 1:05an injection, I think that is the biggest thing.
  23. 1:08You wouldn't start swimming world or white watches
  24. 1:10and still eat the same foods that you always did eat.
  25. 1:14So just use this as a tool.
  26. 1:17For me, it's completely caught the food noise out.
  27. 1:20So I would, I am going through the menopause as well.
  28. 1:24You know, that does have a huge impact on my body.
  29. 1:27So at certain times of the day, I will crave chocolate
  30. 1:30or just something like that, like a sugar rush.
  31. 1:33So instead of that now, I don't get that, which is really good.
  32. 1:39And I've got a lot more energy, so I'm able to move around
  33. 1:42a lot more than I did.
  34. 1:44I'm sleeping better overnight because before I wasn't sleeping,
  35. 1:47but because of my activities in the day,
  36. 1:49I am sleeping better overnight now.
  37. 1:51So all of this does just start to happen for you.
  38. 1:57I think that's what's happened for me.
  39. 1:59I can only talk from experience.
  40. 2:00We are all different.
  41. 2:01Some people are saying this isn't working for them.
  42. 2:04Some people are saying they're switching to other things.
  43. 2:06But I can only tell you what I'm going through.
  44. 2:10And that's all I'm documenting this for,
  45. 2:12is to just, if you are struggling,
  46. 2:15you may hear something I say, I may resonate with you,
  47. 2:18I may say something that you think,
  48. 2:20oh yeah, maybe I could try that.
  49. 2:22So it's a bit of a long winded pose.
  50. 2:23I do apologise.
  51. 2:24But the fact is I have lost, yes, it's coming up slowly,
  52. 2:28but it's still a lost every single week.
  53. 2:31So when you think about it, this is like my fourth injection,
  54. 2:35but it's not my full cycle.
  55. 2:37So I haven't completed the whole month yet,
  56. 2:39and I'm nearly as well.
  57. 2:40I think I'm a stone down now.
  58. 2:42So that's amazing, you know, that's what I wanted to achieve.
  59. 2:45I didn't expect miracles.
  60. 2:47I don't want to lose weight at a massive amount.
  61. 2:52I don't want to shock my body.
  62. 2:54I don't.
  63. 2:55So I want to do it like this.
  64. 2:56So for me, this is working.
  65. 2:59I hope you're following along.
  66. 3:00If you are welcome, if you're not, please give me a follow.
  67. 3:03You know, like I said, we can help each other.
  68. 3:06And yeah, I hope I've said something to help some of you today.
  69. 3:09But a loss for me this week is fantastic.
  70. 3:13So yeah, I'll see what next week brings,
  71. 3:15and we'll see where we're at.
  72. 3:16Please drop your comments and I love reading them.

@itsmevon49's Wegovy week 4 update, fact-checked

itsmevon

TikTok creator

33.2K viewsWatch on TikTok

Quick answer

The creator is a menopausal woman using semaglutide 2.4mg (Wegovy) for weight management, currently in her fourth injection cycle. She reports approximately 2kg of weight loss over four weeks, which is within the expected range for early treatment but below the mean seen in clinical trials, likely reflecting dose titration still in progress. Her described benefits, including reduced food cravings, improved sleep, and increased activity, are consistent with documented pharmacological and secondary effects of semaglutide in clinical literature.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @itsmevon49's Wegovy week 4 update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@itsmevon49's Wegovy week 4 update, fact-checked" from itsmevon. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is a menopausal woman using semaglutide 2.

The reason this review is not generic is the source wording and the canonical claim label "glp1 week 4 of wegovy i have been making better food choices for." In this clip, the useful excerpt is: "From a day late, having a heart attack guys." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The STEP 1 trial (Wilding et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is a menopausal woman using semaglutide 2.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is a menopausal woman using semaglutide 2.4mg (Wegovy) for weight management, currently in her fourth injection cycle. She reports approximately 2kg of weight loss over four weeks, which is within the expected range for early treatment but below the mean seen in clinical trials, likely reflecting dose titration still in progress. Her described benefits, including reduced food cravings, improved sleep, and increased activity, are consistent with documented pharmacological and secondary effects of semaglutide in clinical literature.
  • Semaglutide has a half-life of roughly 7 days: a 24-hour missed dose does not require doubling up and produces no meaningful drop in drug concentration.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% body weight over 68 weeks, but early-week results vary significantly by individual, titration stage, and lifestyle factors.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide has a half-life of roughly 7 days: a 24-hour missed dose does not require doubling up and produces no meaningful drop in drug concentration.
  • The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% body weight over 68 weeks, but early-week results vary significantly by individual, titration stage, and lifestyle factors.
  • Rubino et al. (2022, JAMA) found patients regained approximately two-thirds of lost weight within one year of stopping semaglutide without sustained behavioral changes, supporting the creator's 'tool not a cure' framing.
  • Blundell et al. (2017, Diabetes, Obesity and Metabolism) documented that semaglutide measurably reduces food craving scores on validated appetite scales, giving scientific grounding to the 'food noise' description.
  • Roughly 44% of Wegovy users experience nausea in early weeks (Wilding et al., 2021): the creator did not mention side effects, which is a notable omission for followers in early treatment stages.
  • Menopausal status affects metabolic rate, fat distribution, and cardiovascular risk, and should be disclosed to a prescribing clinician when starting GLP-1 therapy, not managed based on social media comparisons.
  • FormBlends does not endorse compounded semaglutide as equivalent to brand-name Wegovy. Regulatory and formulation differences exist and patients should discuss all options with a licensed prescriber.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @itsmevon49 actually say?

She posted her week-four Wegovy update a day late because she missed her injection window. Her immediate response: panic, then calm. "It is what it is," she said, and moved on. She reported losing roughly two kilograms over the month, attributed it to reduced food cravings, better sleep, and more movement, and framed the drug explicitly as "just a tool" that requires changing your relationship with food. She also mentioned going through menopause and described Wegovy cutting what she called "food noise," particularly evening sugar cravings. Her core advice to followers was simple: relax, adjust your mindset, and don't expect the injection alone to do all the work.

Does the science back this up?

Largely, yes. The "tool not a magic fix" framing is one of the more honest things a GLP-1 user has said on TikTok. Clinical data consistently shows that lifestyle changes amplify semaglutide's effects, and that outcomes drop when patients stop without maintaining habits.

On the missed dose specifically: Novo Nordisk's prescribing guidance states that if more than five days have passed since a missed weekly dose, skip it and resume on the regular schedule. If fewer than five days, take it as soon as possible. She was 24 hours late, well within the acceptable window. The pharmacokinetics of semaglutide support this: the drug has a half-life of approximately one week, meaning a single day's delay produces a negligible dip in plasma concentration. Davies et al. (2021, Diabetes Care) confirmed that once-weekly dosing produces stable steady-state levels that tolerate minor timing variation without clinical consequence.

Her weight loss of roughly two kilograms in four weeks sits at the lower end of what STEP 1 trial participants experienced in early weeks, but weight loss is non-linear and individual variation is well-documented (Wilding et al., 2021, New England Journal of Medicine).

What did they get wrong (or right)?

She got a lot right. The "tool" framing is accurate and clinically supported. Semaglutide works primarily by slowing gastric emptying, suppressing appetite via GLP-1 receptor agonism in the hypothalamus, and reducing food-reward signaling. It does not rewrite your diet for you. The STEP 1 trial made this explicit: participants who combined the drug with behavioral intervention lost significantly more weight than those without structured support.

Her description of reduced "food noise" is also real. This isn't anecdote. Blundell et al. (2017, Diabetes, Obesity and Metabolism) demonstrated that semaglutide reduces appetite and food craving scores on validated measures. The menopause mention is worth noting too. Hormonal shifts during perimenopause and menopause affect appetite regulation, fat distribution, and insulin sensitivity, so her experience of heightened cravings pre-Wegovy has a biological basis.

What she glossed over: she didn't mention side effects at all. Nausea affects roughly 44% of Wegovy users in early weeks (Wilding et al., 2021). Viewers starting week four expecting smooth sailing might be surprised. That omission isn't dangerous, but it's incomplete.

What should you actually know?

Missing a single weekly dose of semaglutide by 24 hours is clinically insignificant. Do not double-dose to compensate. That is explicitly contraindicated in prescribing guidance and could increase gastrointestinal side effects without adding therapeutic benefit.

The behavioral component she describes is not optional for most people. A 2022 analysis by Rubino et al. (JAMA) found that participants who stopped semaglutide regained two-thirds of lost weight within a year when lifestyle support was withdrawn. The drug reduces appetite signals; it does not permanently alter the habits that drive eating behavior.

On menopause: if you are perimenopausal or postmenopausal and considering GLP-1 therapy, that context matters for your prescriber. Hormonal status influences metabolic rate, weight distribution, and cardiovascular risk, all of which affect how your clinician should monitor your progress. Bring it up. Do not rely on TikTok timelines to benchmark your results, including this one. Two kilograms in four weeks is fine. It might also be more or less for you, and neither outcome tells you whether the drug is working or failing.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

itsmevon · TikTok creator

33.2K views on this video

Week 4 of Wegovy. I have been making better food choices for the past few weeks and definitely moving around more. Instead of taking my car everywhere I will walk if I feel it’s doable. Small changes!

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide has a half-life of roughly 7 days: a 24-hour?

Semaglutide has a half-life of roughly 7 days: a 24-hour missed dose does not require doubling up and produces no meaningful drop in drug concentration.

What does the video say about the step 1 trial (wilding et al., 2021, nejm) showed?

The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% body weight over 68 weeks, but early-week results vary significantly by individual, titration stage, and lifestyle factors.

What does the video say about rubino et al. (2022, jama) found patients regained approximately two-thirds?

Rubino et al. (2022, JAMA) found patients regained approximately two-thirds of lost weight within one year of stopping semaglutide without sustained behavioral changes, supporting the creator's 'tool not a cure' framing.

What does the video say about blundell et al. (2017, diabetes, obesity?

Blundell et al. (2017, Diabetes, Obesity and Metabolism) documented that semaglutide measurably reduces food craving scores on validated appetite scales, giving scientific grounding to the 'food noise' description.

What does the video say about roughly 44% of wegovy users experience nausea in early weeks?

Roughly 44% of Wegovy users experience nausea in early weeks (Wilding et al., 2021): the creator did not mention side effects, which is a notable omission for followers in early treatment stages.

What does the video say about menopausal status affects metabolic rate, fat distribution,?

Menopausal status affects metabolic rate, fat distribution, and cardiovascular risk, and should be disclosed to a prescribing clinician when starting GLP-1 therapy, not managed based on social media comparisons.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by itsmevon, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.